Not Yet Recruiting PHASE3 INTERVENTIONAL 1-arm NCT06188455

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Clinical Study of Fluzopalil Combined With Apatinib for Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Sponsor: The First Affiliated Hospital of Xiamen University

Conditions Ovarian Cancer

Interventions Apatinib Mesylate Tablets Fluzoparib Capsules

Updated 3 times since 2024 Last updated: Dec 18, 2023 Started: Dec 1, 2024 Primary completion: Dec 1, 2025 Completion: Dec 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Ovarian Cancer, this trial is actively recruiting participants. The trial is conducted by The First Affiliated Hospital of Xiamen University and has accumulated 3 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE3
Feb 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The First Affiliated Hospital of Xiamen University

Data source: The First Affiliated Hospital of Xiamen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.